Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer (Cancer Research (2010) 70, (347-56) DOI: 10.1158/0008-5472.CAN-09-1252);Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer

Cancer Research

Volumn 70, Issue 1, 2010, Pages 347-356

  Swift, Stephanie L ^a   Burns, Julie E ^a   Maitland, Norman J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 1; CYTOKERATIN 10; CYTOKERATIN 14; CYTOKERATIN 18; NEUROTENSIN RECEPTOR; SORTILIN;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE SECTION; UPREGULATION;

EID: 75149164771     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0036     Document Type: Erratum

References (39)

1. Robinson EJ, Neal DE, Collins AT. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 1998;37:149-60.
2. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers 2002;66:184-99.
3. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46 Suppl 1:67-75S.
4. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298-307.
5. Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997;31:183-92.
6. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U S A 1994;91:4673-7.
7. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF, Jr. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80:2109-19.
8. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-68.
9. Vias M, Burtt G, Culig Z, Veerakumarasivam A, Neal DE, Mills IG. A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate 2007;67:190-202.
10. Falkmer S, Askensten U, Grimelius L, Abrahamsson PA. Cytochemical markers and DNA content of neuroendocrine cells in carcinoma of the prostate gland during tumour progression. Acta Histochem Suppl 1990;38:127-32.
11. Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L, Na Y. Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol 2007;29:128-38.
12. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992;147:804-7.
13. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001;21:8385-97.
14. Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 1999;20:302-9.
15. Chalon P, Vita N, Kaghad M, et al. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett 1996;386:91-4.
16. Vita N, Laurent P, Lefort S, et al. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett 1993;317:139-42.
17. Morinville A, Martin S, Lavallee M, Vincent JP, Beaudet A, Mazella J. Internalization and trafficking of neurotensin via NTS3 receptors in HT29 cells. Int J Biochem Cell Biol 2004;36:2153-68.
18. Chabry J, Gaudriault G, Vincent JP, Mazella J. Implication of various forms of neurotensin receptors in the mechanism of internalization of neurotensin in cerebral neurons. J Biol Chem 1993;268:17138-44.
19. Morris NJ, Ross SA, Lane WS, et al. Sortilin is the major 110-kDa protein in GLUT4 vesicles fromadipocytes. J Biol Chem1998;273:3582-7.
20. Berthon P, Cussenot O, Hopwood L, Le Duc A, Maitland NJ. Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: differentiation pattern of non-tumorigenic cell lines. Int J Oncol 1995;6:333-43.
21. Maitland NJ, Macintosh CA, Hall J, Sharrard M, Quinn G, Lang S. In vitro models to study cellular differentiation and function in human prostate cancers. Radiat Res 2001;155:133-42.
22. 1-integrin expression. J Cell Sci 2001;114:3865-72.
23. van Leenders GJ, Dijkman H, Hulsbergen-van de KC, Ruiter D, Schalken J. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80:1251-8.
24. Dal Farra C, Sarret P, Navarro V, Botto JM, Mazella J, Vincent JP. Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int J Cancer 2001;92:503-9.
25. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but nontransformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31:14-24.
26. Lang SH, Hyde C, Reid IN, et al. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002;52:253-63.
27. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001;195:563-70.
28. Botto JM, Sarret P, Vincent JP, Mazella J. Identification and expression of a variant isoformof the levocabastine-sensitive neurotensin receptor in the mouse central nervous system. FEBS Lett 1997;400:211-4.
29. Perron A, Sarret P, Gendron L, Stroh T, Beaudet A. Identification and functional characterization of a 5-transmembrane domain variant isoform of the NTS2 neurotensin receptor in rat central nervous system. J Biol Chem 2005;280:10219-27.
30. You L, Yin J. Patterns of regulation from mRNA and protein time series. Metab Eng 2000;2:210-7.
31. Myers RM, Shearman JW, Kitching MO, Ramos-Montoya A, Neal DE, Ley SV. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. ACS Chem Biol 2009;4:503-25.
32. Amorino GP, Deeble PD, Parsons SJ. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene 2007;26:745-56.
33. CarrawayRE, Hassan S.Neurotensin receptor binding and neurotensininduced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress. Regul Pept 2007;141:140-53.
34. Evans GS, Chandler JA. Cell proliferation studies in the rat prostate: II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation. Prostate 1987;11:339-51.
35. Perron A, Sharif N, Sarret P, Stroh T, Beaudet A. NTS2 modulates the intracellular distribution and trafficking of NTS1 via heterodimerization. Biochem Biophys Res Commun 2007;353:582-90.
36. Perron A, Sharif N, Gendron L, et al. Sustained neurotensin exposure promotes cell surface recruitment of NTS2 receptors. Biochem Biophys Res Commun 2006;343:799-808.
37. Massie CE, Adryan B, Barbosa-Morais NL, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007;8:871-8.
38. Salah Z, Maoz M, Cohen I, et al. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J 2005;19:62-72.
39. Nagakawa O, Ogasawara M, Fujii H, et al. Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett 1998;133:27-33.